About Claris Lifescience
Claris Lifesciences is one of the largest sterile injectables pharmaceutical companies in India with a market presence in 76 countries worldwide. We primarily manufacture and market products across multiple markets, and therapeutic segments. A significant majority of these products are generic drugs that are capable of being directly injected into the human body and are predominantly used in the treatment of critical illnesses.
About Claris Lifescience IPO
|CLARIS LIFESCIENCES LIMITED
|Symbol – Series
||Nov 24, 2010 to Nov 26 2010
|Post issue Modification Period
||Public Issue Of [.] Equity Shares Of Rs. 10 Each Aggregating To Rs. 3000 Million.(including anchor portion of 18,43,003 equity shares.)
||100% Book Building
||Rs 278 to Rs 293
||22 Equity Shares
|Minimum Order Quantity
||22 Equity Shares
|Maximum Subscription Amount for Retail Investor
|IPO Market Timings
||10.00 a.m. to 5.00 p.m.
||IPO Grade 3
||Fitch Ratings India Private Limited
|Book Running Lead Manager
||Enam Securities Private Limited,Edelweiss Capital Limited,JM Financial Consultants Private Limited,ICICI Securities Limited.
Claris Lifescience IPO Allotment Status
Cupid Ltd has informed the marke that the Company has been awarded order for Supply 61.24 Million pcs of condoms (Nirodh) from the Ministry of Health and Family Welfare, Government of India aggregating amounting to Rs. 963.38 Lacs.
Suven Life Sciences informed the market that it has secured 5th product patent from US patent office for their NCE to treat Central Nervous System (CNS) disorders, With this new patent , Suven has a total of 5 granted US product patents for their NCEs in CNS therapy. These granted patents are exclusive intellectual property of Suven.
Commenting on this Suven Life Science MD has told that “We are very pleased by the grant of this patent to Suven by US Patent Office for out pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $ 20 billion market potential globally”.
Cadila Healthcare Ltd has informed the market that the board has come out with April 06, 2010 as Record Date for the purpose of determining the members entitle to Bonus equity shares as recommended by the Board and approved by the shareholders in proportion of one new equity share of Rs. 5/- each fully paid-up for every two equity shares of Rs. 5/- each fully paid-up held by them.(1:2)
Cadila Healthcare Ltd (CHL) has informed the market that the company has come out with a decision on the meeting that was held on on Feb 25th hat they will allocate 1 (One) Equity Share of Rs. 5/- each fully paid-up for every 2 (Two) Equity Shares of Rs. 5/- each based on the record date that will eb announced later.
Strides Arcolab Ltd has informed the market that they have launched on Retail basis of Starflu (Oseltamivir) for the treatment of ‘Influenza – A (H1N1).This will be now available in all registered pharma shops.This has given some hike in stock prize , this is second company to come out with retail launch of swine flu cure.
Natco Pharma launches Swine Flu medicine its medicine and not a Vaccine , Its called NatFlu which is generic version of TamiFlu – Oseltamivir whioch is considered as a cure for Swine Flu .They are costing 480 rs per Bottle which has 10 capsules and they said its available in all licensed Pharmacies.
>Natco Pharma rose after the US drug regulator accepted new drug application from its partner Mylan Inc for a generic version of Teva Pharmaceutical’ blockbuster Copaxone
>Anuh Pharma rose after the company said its manufacturing facility will receive European Good Manufacturing Practices certificate.
>Orchid Chemicals & Pharmaceuticals rose after the company got US drug regulators’ nod for piperacillin-tazobactam antibiotic in injection forms with a 180-day marketing exclusivity.
Panacea Biotec Ltd has informed the market that the Company has received a largest order from UNICEF for 3 years starting from 2010 for supply of its EasyFive (pentavalent vaccine),the orderis valued around USD 222.37 million (over Rs 1,067 Crores).
What is EasyFive Vaccine from Panacea
EasyFive is world’s first fully liquid pentavalent vaccine introduced in India by Panacea Biotec in January 2005, which immunizes children against five dreadful diseases (Diptheria, Tetanus, wholecellPertussis, Hepatitis B and Hemophilus Influenza Type b) of early childhood.
Divis lab which was battered almost for 2 days because of poor qtr performance had also other bad news that was spread by mails and messages circulating regarding an alleged pledging of promoter’s shareholding in the Company with India Bulls or some institution, After this Divi’s clarified it to the stock exchange that there is no pledge, whatsoever, of any shares held by the promoter in Divi’s Laboratories Ltd. Infact, the promoter does not have any loans from any bank or institution.Not sure if they are followign this has standard now to batter the stock and then get it at higher price.
Dabur India informed the market that they had bought 72.15% stake in Fem Care Pharma for Rs 203.7 crore ,which will be paid in full cash , They want to use this as the platform to enter into skin care market.They still have to buy an addtional 20 percent stake in Fem care which is required by takeover regulations act of india.Fem care Pharma closed the market yesterday at 656 or so up by 13 rs.
Panacea Biotec informed the market that it has received order worth 35 million US dollars from UNICEF to supply pentavalent vaccines, the order is almost worth 140 crore rs in indian money, This is forst time i have seen a unicef order coming to a indian medical company .On the financial side The company’s net profit fell 27.9% to Rs 34.05 crore on 3.8% decline in sales to Rs 224.48 crore in Q1 June 2008 over Q1 June 2007.
Biocon net profit declines 33.10% to Rs 30.01 crore in the first Qtr for june ending 2008-2009 compared to Rs 44.86 crore in same QOQ Previous year 2007. Sales declined 2.74% to Rs 221.18 crore in the first Qtr for june ending 2008-2009 compared to Rs 227.40 crore in same QOQ Previous year 2007.
Jubilant Organosys announces its first QTR Results for 2008-2009.Net profit was at Rs 12.76 crore versus Rs 142.9 crore when compared to the same QTR for previous year , ok i understand is the figure wrong or something no it is right they had a huge forex loss of 107.6 crore this qtr but the same was like 82 crore gain previous year same qtr. Q1 net sales is at Rs 826.6 crore versus Rs 540 crore on YoY basis.
So on thursday ranbaxy was down like to 216 rs because ranbaxy told the market that they are not interested in hostile takeover , may be thats the strategy they say it and get orchid chemical price down and had Solrex acquire 3.32% stake in Orchid Chemicals on Friday, reports CNBC-TV18. The company shareholding in the Indian Pharmaceuticals major has reached 14.72%, which is close to 15% open offer trigger. Sources said other Ranbaxy promoter group companies might have also garnered shares in Orchid.
Orchid Chemicals & Pharmaceuticals Ltd has informed the market that the Company is announcing, on April 10, 2008 the formation of its wholly owned subsidiary in Japan called Orchid Pharma Japan K K (Orchid Japan). Orchid Japan, is headquartered in Tokyo, will drive Orchid’s foray into the high potential and growing Japanese generics market.
Ranbaxy commented that they don’t believe in hostile takeover , this statement was enough to sell orchid chemicals which rose from prev week of 140 rs or so to this weeks 240 rs .There was speculation that Solrex Pharmaceuticals, which recently increased its holding in Orchid to 11.4% is controlled by Ranbaxy. Orchid stock had spurted in the last two days on such buzz.The acquisition of Orchid shares by Solrex Pharmaceuticals through open market purchases raised expectations that Ranbaxy plans a hostile takeover of Orchid Chemicals
Orchid Chemicals was hammered today by 40 percent or so and its trading at 128 and it closed the market on friday at 208.60 , infact hindu has reconmmended a Buy on this stock on saturday .The traded quantity in the stock is unusally high.
Hindu Recommends a Buy for Orchid Chemicals on saturday
Update: Reason for the sell off
The Orchid management told CNBC-TV18 that they have sold 7% of their stake due to margin calls.After Bear Stearns transferred over 10 lakh Orchid shares, the stock price was under considerable pressure. As the margin calls positions are being cleared, they have no further plans to sell more shares, the management said.
Nicholos piramal which changed its name to Piramal Healthcare like previous week or so now has a new identity or logo , They call the identity as a Gyan Mudra .The stock price of Nicholos piramal went up by 16.50 rs or 6 percent in BSE today.You can see the new Gyan Mudra identity of Piramal Healthcare in the picture below.
About Aurobindo Pharma
|One of the largest API manufacturers in Asia, Aurobindo Pharma has commercialised over hundred APIs. Aurobindo’s products are spread over six major areas encompassing Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics.
Aurobindo’s R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. In the process, Aurobindo develops new drug delivery systems, dosage formulations and applies new technology for better processes.
Sector :Pharmaceuticals – Bulk Drugs
Aurobindo Pharma is trading at 304 rs or so which was on march 7th 2008 and its just 7 times the EPs of 43 or so , while considering other phrama company at this price its considered a good buy.
Track Aurobindo Stock Price here.
•Reduction of excise duty from 16% to 8% is a positive for all pharma companies .
•Emphasis on allocating funds for the eradication of HIV/AIDS and polio .
Nicholas Piramal India Ltd informed the market that at its meeting held on March 03, 2008, has approved the proposal for change of name of the Company from “Nicholas Piramal India Ltd” to “Piramal Healthcare Ltd”.The Health Sector dint see much red sides today and this scrip also dint go much down today.
Shasun Chemicals & Drugs Ltd saw some movement in the price today after it informed the market that they have entered into a non-exclusive licensing agreement with Merck & Co., Inc.This will bring more business from Merck.
Jubilant Organosys Ltd informed the market that it has bagegd new contracts worth US $ 92 million for its Proprietary Products and Exclusive Synthesis segment under CRAMS business for the present calendar year (CY 2008).
Bliss GVS Pharma rose 5433.33% to Rs 8.30 crore in Qtr Dec 2007 compared to Rs 0.15 crore QOQ in Dec 2006. Sales rose 2084.31% to Rs 22.28 crore in Qtr Dec 2007 compared to Rs 1.02 crore QOQ in Dec 2006.
Orchid Chemicals & Pharmaceuticals rose 91.07% to Rs 54.11 crore in qtr Dec 2007 as against Rs 28.32 crore in qtr Dec 2006. Sales rose 39.36% to Rs 332.69 crore in qtr Dec 2007 as against Rs 238.73 crore in qtr Dec 2006.